Purification specialist BIA Separations to become part of Sartorius
![](/46/pdcnewsitem/08/51/76/pexels-bongkarn-thanyakij-3740403%20(2).jpg)
BIA Separations will be Sartorius's center of excellence for purification of cell and gene therapeutics.
Sartorius has agreed to merge purification specialist BIA Separations into its subgroup Sartorius Stedim Biotech in a transaction totaling 360 million euro.
BIA Separations develops and manufactures market-leading products for purification and analysis of large biomolecules, such as viruses, plasmids and mRNA, which are used in cell and gene therapies and other advanced therapies.
The company's technology for manufacturing scale purification is already in use to produce the first commercialized advanced therapeutics. The company also has a strong presence with such novel drug candidates in the clinical pipeline.
"Combining the teams and technologies of Sartorius and BIA will create a premium offering for the manufacturing of advanced therapies," commented Joachim Kreuzburg, CEO of Sartorius.
Founded in 1998, BIA Separations has invented and commercialized the unique CIM (Convective Interaction Media) monolith chromatography technology. In addition, it offers analytical technologies for process monitoring and optimization.
At its headquarters in Ajdovščina, Slovenia, BIA employs a workforce of some 120 people. Following its strong growth, the company is currently more than quadrupling its production capacity, which will become operational during the beginning of 2021. Furthermore, the company is significantly expanding its market-leading process development services.
Aleš Strancar, founder and CEO of BIA Separations, commented: "I am especially excited that our combined R&D groups will result in one of the strongest development teams in bioprocessing worldwide, which will rapidly increase the number of products under development while substantially reducing time-to-market."
Expecting continued very strong double-digit sales growth over the next few years, BIA is forecasted to earn sales revenue of approximately 25 million euro in 2020.
![Sartorius Stedim Biotech GmbH](https://www.cphi-online.com/c267627th_S-comp267627.jpg)
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance